ACDIMA sells 10% of Saudi drugmaker SPIMACO for SAR 326M
What's the deal? The Arab Company for Drug Industries and Medical Appliances (ACDIMA) has sold a 9.998% stake in Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) for SAR 326.34 million. The 11.99 million shares went to two investment vehicles managed by Alistithmar CapitalDealroom has a profile for this one. Try Dealroom →, according to a bourse filing.
Who's involved? ACDIMA is a pan-Arab shareholding company established by a resolution from the Arab Economic Unity Council. SPIMACO is one of the Kingdom's most prominent pharmaceutical manufacturers. GIB CapitalDealroom has a profile for this one. Try Dealroom → advised ACDIMA on the sale.
The terms: The shares were acquired by Alistithmar Capital Fund for Investment 44 and Alistithmar Capital Fund for Investment 49. The deal closed on July 21, 2026, executed through negotiated trades on the Saudi Exchange (Tadawul).
Why this structure? Negotiated trades let institutional investors move large blocks of shares at a set price without triggering the volatility of open-market orders. The trades followed Tadawul's Trading and Membership Procedures.
What changes? ACDIMA's stake in SPIMACO drops to roughly 10.5%, keeping it a double-digit shareholder. The sale gives ACDIMA liquidity while preserving a core interest in the company's future performance.
The signal: The entry of Alistithmar Capital's specialised funds points to institutional appetite for exposure to Saudi pharmaceutical manufacturing. It also reflects continued liquidity and institutional activity across the Kingdom's capital markets.
Read more: Mubasher
Image credit: Generated with Gemini
